This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van der Most, R. G. Articles by Lake, R. A. Search for Related Content PubMed PubMed Citation Articles by van der Most, R. G. Articles by Lake, R. A. Related Collections Cancer Immunology Cancer Immunology: Adaptive Immunity Cancer Immunology: Immunotherapy

Cranking the Immunologic Engine with Chemotherapy: Using Context to Drive Tumor Antigen Cross-Presentation towards Useful Antitumor Immunity

School of Medicine and Pharmacology and Western Australian Institute for Medical Research, University of Western Australia, Sir Charles Gairdner Hospital, Nedlands, Perth, Australia

Requests for reprints: Richard A. Lake, School of Medicine and Pharmacology and Western Australian Institute for Medical Research, University of Western Australia, 4th Floor, G Block, Sir Charles Gairdner Hospital, Nedlands, Perth 6009, Australia. Phone: 61-8-9346-3127; Fax: 61-8-9346-2816; E-mail: rlake{at}cyllene.uwa.edu.au.

This review shows how tumor antigen cross-presentation is affected by the major therapeutic modalities including chemotherapy, radiotherapy, and surgery. We argue that this process could affect the way that a tumor works as its own cellular vaccine, and that it is differentially modulated by the choice of treatment. (Cancer Res 2006; 66(2): 601-4)

This article has been cited by other articles:

				S. A. Dromi, M. P. Walsh, S. Herby, B. Traughber, J. Xie, K. V. Sharma, K. P. Sekhar, A. Luk, D. J. Liewehr, M. R. Dreher, et al. Radiofrequency Ablation Induces Antigen-presenting Cell Infiltration and Amplification of Weak Tumor-induced Immunity Radiology, April 1, 2009; 251(1): 58 - 66. [Abstract] [Full Text] [PDF]

				R. L. VanOosten and T. S. Griffith Activation of Tumor-Specific CD8+ T Cells after Intratumoral Ad5-TRAIL/CpG Oligodeoxynucleotide Combination Therapy Cancer Res., December 15, 2007; 67(24): 11980 - 11990. [Abstract] [Full Text] [PDF]

				M. S. Bijker, S. J. F. van den Eeden, K. L. Franken, C. J. M. Melief, R. Offringa, and S. H. van der Burg CD8+ CTL Priming by Exact Peptide Epitopes in Incomplete Freund's Adjuvant Induces a Vanishing CTL Response, whereas Long Peptides Induce Sustained CTL Reactivity J. Immunol., October 15, 2007; 179(8): 5033 - 5040. [Abstract] [Full Text] [PDF]

				H. Zhong, B. Han, I. L. Tourkova, A. Lokshin, A. Rosenbloom, M. R. Shurin, and G. V. Shurin Low-Dose Paclitaxel Prior to Intratumoral Dendritic Cell Vaccine Modulates Intratumoral Cytokine Network and Lung Cancer Growth Clin. Cancer Res., September 15, 2007; 13(18): 5455 - 5462. [Abstract] [Full Text] [PDF]

				N. Tsuda, D. Z. Chang, T. Mine, C. Efferson, A. Garcia-Sastre, X. Wang, S. Ferrone, and C. G. Ioannides Taxol Increases the Amount and T Cell Activating Ability of Self-Immune Stimulatory Multimolecular Complexes Found in Ovarian Cancer Cells Cancer Res., September 1, 2007; 67(17): 8378 - 8387. [Abstract] [Full Text] [PDF]

				G. C. Prendergast and E. M. Jaffee Cancer Immunologists and Cancer Biologists: Why We Didn't Talk Then but Need to Now Cancer Res., April 15, 2007; 67(8): 3500 - 3504. [Abstract] [Full Text] [PDF]

				I. Melero, A. Arina, O. Murillo, J. Dubrot, C. Alfaro, J. L. Perez-Gracia, M. Bendandi, and S. Hervas-Stubbs Immunogenic Cell Death and Cross-Priming Are Reaching the Clinical Immunotherapy Arena Clin. Cancer Res., April 15, 2006; 12(8): 2385 - 2389. [Full Text] [PDF]